Phathom Pharmaceuticals(PHAT)

Search documents
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
Globenewswireยท 2025-08-07 10:59
Core Insights - Phathom Pharmaceuticals reported significant revenue growth in Q2 2025, with net revenues of $39.5 million, up from $7.3 million in Q2 2024, driven by the commercial success of VOQUEZNA products [5][6][11] - The company aims to achieve profitability by 2026, supported by a refined commercial strategy focusing on high-value prescribers and strong prescription trends [2][6][11] Business Highlights - Over 580,000 VOQUEZNA prescriptions have been filled to date, reflecting a 49% increase since the last earnings report [6][7] - Approximately 173,000 VOQUEZNA prescriptions were filled in Q2 2025, representing a 36% sequential growth from Q1 2025 [7] - The prescriber base has expanded, with over 29,300 unique healthcare providers writing prescriptions, a 24% increase since the last quarterly update [7] Financial Performance - R&D expenses for Q2 2025 were $9.1 million, an increase from $7.4 million in Q2 2024, primarily due to one-time restructuring charges [11] - SG&A expenses rose to $85.3 million in Q2 2025 from $75.9 million in Q2 2024, driven by higher personnel-related costs [11] - The net loss for Q2 2025 was $75.8 million, compared to $91.4 million in Q2 2024, with a non-GAAP adjusted net loss of $56.5 million [11][19] Market Position and Strategy - The FDA granted 10-year New Chemical Entity exclusivity for VOQUEZNA, extending market protection until May 2032, which is expected to delay generic competition until at least 2033 [7] - The company has shifted its sales strategy to prioritize gastroenterologists over primary care physicians to enhance prescriber engagement [7] Future Outlook - Phathom expects full-year 2025 revenue to be between $165 million and $175 million, based on strong prescription trends and a refined commercial strategy [6][11] - The company anticipates non-GAAP operating expenses to decrease to less than $60 million in Q3 2025 and less than $55 million in Q4 2025 [11]
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Globenewswireยท 2025-07-28 12:00
Core Viewpoint - Phathom Pharmaceuticals, Inc. will host a live webcast on August 7, 2025, to report its second quarter 2025 financial results and provide a business update [1]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3]. - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) [3]. - Vonoprazan is marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions, including heartburn relief associated with Non-Erosive GERD and treatment of H. pylori infection [3].
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
Seeking Alphaยท 2025-06-25 08:54
Group 1 - The company has a strong academic foundation with an MBA in Finance and an MD, enhancing its expertise in the financial sector [1] - The company operates as a registered investment advisor and professional money manager, focusing on income investing and biotech/pharma investing [2] - The company emphasizes community building for sharing and thriving breakthrough investment ideas in the biotech/pharma industry [2] Group 2 - The company provides in-depth analysis of income investing and long-term takeover potential biotech/pharma stocks, identifying both short-term and long-term investment opportunities [3] - The company offers tailored biotech analysis and regular portfolio trade alerts, facilitating investor engagement and confidence in navigating biotech investments [4] - The company has authored a top-selling book on biotech investing and provides educational resources through an online course [4]
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Globenewswireยท 2025-06-23 11:59
Core Insights - Phathom Pharmaceuticals has appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary, bringing extensive legal expertise in the pharmaceutical industry [1][2][3] Company Overview - Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases [6] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), marketed in the U.S. as VOQUEZNA for various gastrointestinal conditions [6] Leadership Background - Anne Marie Cook has a strong background in pharmaceutical law, having served as Senior Vice President and General Counsel at Sage Therapeutics, and held legal leadership roles at Aegerion, ViaCell, and Biogen [2][4] - Cook's experience includes overseeing legal activities related to commercialization, regulatory compliance, intellectual property, and corporate governance [4] Strategic Vision - The CEO of Phathom, Steven Basta, expressed confidence that Cook's skills will significantly impact the company's growth and corporate strategy [3] - Cook emphasized her commitment to helping Phathom redefine the standard of care in acid-related gastrointestinal diseases and create value for stakeholders [3][4]
Phathom Pharmaceuticals(PHAT) - 2023 Q4 - Earnings Call Presentation
2025-06-19 09:06
Business Overview - VOQUEZNA aims to transform the landscape of acid-related disorders, targeting a US potential peak revenue opportunity of over $3 billion[11, 12] - The company is experiencing early success with its pricing and access strategy[20] - VOQUEZNA launch is off to a strong start, with over 14,000 total demand[18] Commercial Launch Progress - Over 3,800 filled VOQUEZNA scripts[18] - Over 1,200 unique VOQUEZNA writers[18] - The company has achieved approximately 38% commercial coverage, representing about 60 million commercial lives covered[21] Financial Results - The company had $3814 million in cash as of December 31, 2023[27] - Q4 2023 net revenues were $07 million[27] - Full Year 2023 Non-GAAP R&D expenses were $714 million, and Non-GAAP SG&A expenses were $1010 million[27] - Full Year 2023 GAAP net loss was ($201592) thousand, and Non-GAAP adjusted net loss was ($129713) thousand[29]
Phathom Pharmaceuticals(PHAT) - 2024 Q1 - Earnings Call Presentation
2025-06-19 09:06
Business Update - VOQUEZNA has achieved significant progress in clinical superiority, brand awareness, and patient access during its launch phase[10] - As of April 26, 2024, over 43,000 prescriptions have been written and over 17,500 prescriptions have been filled for VOQUEZNA[12] - VOQUEZNA has secured commercial coverage for approximately 72 million lives[13] - The company is preparing for a potential Non-Erosive GERD launch, with an action date of July 19, 2024, targeting a market of approximately 15 million adults[14] Commercial Launch Progress - Total VOQUEZNA demand includes over 43,000 unique prescriptions written and over 17,500 filled prescriptions[21] - The number of unique VOQUEZNA writers has reached over 3,800[21] - There has been consistent monthly growth in filled prescriptions, reaching approximately 7,520 as of April 26, 2024[26] - Commercial coverage has expanded to 48%, covering approximately 72 million lives, including Cigna Healthcare with over 9 million lives covered[28] Financial Results - Net revenues for Q1 2024 were $1.9 million[36] - Non-GAAP SG&A expenses for Q1 2024 were $57.6 million[40] - The company reported $322.2 million in cash and cash equivalents as of March 31, 2024, which is expected to fund operations through the end of 2026[43]
Phathom Pharmaceuticals(PHAT) - 2024 Q3 - Earnings Call Presentation
2025-06-19 09:05
Business & Product Updates - VOQUEZNA prescriptions filled reached over 143,000[9, 21] - Commercial coverage expanded to over 120 million lives[9, 25] - The company successfully completed an equity follow-on, raising $130 million in gross proceeds[9] - Three VOQUEZNA products are approved across three indications[14] Commercial Launch Progress - Filled prescriptions grew significantly in Q3 2024, reaching approximately 69,000, a ~100% increase compared to Q2 2024[20] - Cumulative writers increased to over 12,400 in Q3 2024, a ~70% increase compared to Q2 2024[24] - Over 80% commercial coverage has been established[25] Financial Results - Net revenues for Q3 2024 were $16.4 million[33, 35] - Non-GAAP SG&A expenses were $71.8 million in Q3 2024[37] - Non-GAAP R&D expenses were $7.4 million in Q3 2024[37] - Adjusted net loss for Q3 2024 was $67.85 million, or $1.05 per share[39] - Cash and cash equivalents totaled $334.7 million as of September 30, 2024[40]
Phathom Pharmaceuticals(PHAT) - 2024 Q4 - Earnings Call Presentation
2025-06-19 09:05
Business Performance & Growth - VOQUEZNA achieved over 300,000 filled prescriptions launch-to-date[13, 24] - Commercial coverage exceeds 80%, covering over 120 million commercial lives[9, 41] - Primary Care Physicians (PCPs) are increasingly contributing to prescription growth, with a ~2x increase in PCP awareness[39] - Approximately 70% of prescriptions in Q4 were refills, indicating continued therapy[31] - HCPs reporting patient requests increased by over 55% since the Direct-to-Consumer (DTC) campaign launch[43] Financial Results - Q4 2024 net revenue reached $29.7 million, reflecting an ~81% increase from the previous quarter[50] - The company reported a GAAP net loss of ($74.451) million for Q4 2024 and ($334.326) million for the full year 2024[54] - Non-GAAP adjusted net loss was ($56.376) million for Q4 2024 and ($262.316) million for the full year 2024[54] - Cash and cash equivalents totaled $297.3 million as of December 31, 2024[55] Legal & Development - The FDA acknowledged the Citizen Petition on 12/11/24, related to VOQUEZNA Orange Book listings[16] - The company is developing a strategy for OTC acid control market, which generates ~$3 billion annually[15]
Phathom Pharmaceuticals(PHAT) - 2025 Q1 - Earnings Call Presentation
2025-06-19 09:04
FIRST QUARTER 2025 EARNINGS CONFERENCE CALL Molly Henderson, Chief Financial & Business Officer Robert Breedlove, VP of Finance & Principal Accounting Officer Closing Remarks Steven Basta, President & Chief Executive Officer MAY 2025 NASDAQ: PHAT Today's Agenda Business Update Steven Basta, President & Chief Executive Officer Q1 2025 Commercial & Financial Results 2 Safe harbor This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this p ...
Phathom Pharmaceuticals (PHAT) Earnings Call Presentation
2025-06-19 09:03
CHANGING THE LANDSCAPE IN GI Going beyond to advance treatments for patients with acid-related disorders Corporate Overview Safe harbor statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing and magnitude of planned operating expense reductions and ability to achieve revenue growth and profit from operations and the timing thereof; planned operational changes and organ ...